Kopran Limited (KOPRAN) AI Stock Analysis

• Market Cap: ₹7.72B
• Dividend Yield: 1.87%
• Average Volume (3M): 21.56K
• Price to Earnings (P/E): 22.1
• Beta (1Y): 1.14
• Revenue Growth: -1.83%
• EPS Growth: -41.11%
• Country: IN
• Employees: 842
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.54
• Shares Outstanding: 48,285,606
• 10 Day Avg. Volume: 18,791
• 30 Day Avg. Volume: 21,558
• PEG Ratio: -0.96
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 1.44
• P/FCF Ratio: -67.21
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹165.00
• Price Target Upside: 3.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: ₹165.00 ▲(3.19% Upside)

The overall stock score reflects strong financial performance with growth potential, but is weighed down by bearish technical indicators and moderate valuation metrics. The lack of earnings call data and corporate events further limit the clarity of the investment outlook.

Kopran Limited Business Overview & Revenue Model

Company Description

Kopran Limited is a publicly traded pharmaceutical company based in India. It operates in the healthcare and pharmaceutical sectors, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical products. The company's core products include active pharmaceutical ingredients (APIs), formulations, and over-the-counter (OTC) products. Kopran Limited is committed to delivering quality healthcare solutions and expanding its global presence through innovation and strategic partnerships.

How the Company Makes Money

Kopran Limited generates revenue primarily through the sale of its pharmaceutical products, which include APIs, formulations, and OTC products. The company manufactures these products and distributes them both domestically and internationally, leveraging a network of distributors and strategic partners. Kopran's revenue model is supported by its focus on research and development, which enables the company to expand its product portfolio and enter new markets. Additionally, Kopran engages in contract manufacturing for other pharmaceutical companies, providing an additional revenue stream. Strategic partnerships and collaborations also play a significant role in enhancing the company's market reach and financial performance.

Kopran Limited Financial Statement Overview

Summary

Kopran Limited shows strong revenue growth and operational efficiency. However, challenges in net profit margin and cash flow management slightly dampen the financial outlook. The balance sheet indicates a robust equity position, but there is room for improvement in leveraging equity more effectively.

Income Statement

Kopran Limited has demonstrated steady revenue growth with a notable increase from 2024 to 2025, showing a revenue growth rate of 3.2%. The gross profit margin for 2025 is 35.7%, reflecting efficient cost management. However, net profit margin declined to 6.1% in 2025 from 8.4% in 2024, indicating pressure on net profitability despite higher revenues. The EBIT margin improved significantly to 26.1% in 2025, suggesting enhanced operational efficiency. EBITDA margin decreased slightly to 11.6% in 2025, indicating some challenges in maintaining earnings before amortization and depreciation.

Balance Sheet

The balance sheet reveals a solid equity base, with equity ratio improving to 61.4% in 2025, indicating strong capitalization. The debt-to-equity ratio is 0.29, reflecting prudent leverage. However, the return on equity has decreased to 7.4% in 2025 from 10.4% in 2024, highlighting challenges in generating returns from equity. The overall stability is strong, but there is room for improvement in leveraging equity more effectively.

Cash Flow

Kopran Limited faces challenges in cash flow management, with free cash flow remaining negative in 2025 despite operating cash flow being positive. The free cash flow to net income ratio is -0.35, indicating inefficiencies in converting profits into free cash flows. The operating cash flow to net income ratio is 1.09, suggesting that operating cash flow supports net income, but capital expenditures weigh heavily on free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	6.30B	6.30B	6.10B	5.48B	4.74B	4.81B
Gross Profit	2.25B	2.25B	2.05B	1.86B	1.90B	1.67B
EBITDA	736.51M	729.00M	868.18M	548.77M	980.11M	997.82M
Net Income	385.52M	385.52M	509.56M	272.33M	610.31M	616.06M
Balance Sheet
Total Assets	8.44B	8.44B	7.43B	6.50B	6.11B	4.39B
Cash, Cash Equivalents and Short-Term Investments	258.64M	258.64M	80.91M	126.51M	58.68M	9.35M
Total Debt	1.48B	1.48B	992.28M	752.38M	745.49M	663.02M
Total Liabilities	3.26B	3.26B	2.52B	2.10B	1.85B	1.94B
Stockholders Equity	5.18B	5.18B	4.91B	4.39B	4.26B	2.45B
Cash Flow
Free Cash Flow	0.00	-134.46M	-133.56M	-270.22M	-757.47M	355.37M
Operating Cash Flow	0.00	419.42M	432.58M	340.23M	-334.75M	599.51M
Investing Cash Flow	0.00	-564.28M	-435.52M	-126.50M	-844.15M	-252.79M
Financing Cash Flow	0.00	258.68M	9.88M	-198.44M	1.23B	-345.71M

Kopran Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 159.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Negative. The current price of 159.9 is below the 20-day moving average (MA) of 167.51, below the 50-day MA of 178.76, and below the 200-day MA of 197.24, indicating a bearish trend. The MACD of -6.08 indicates Positive momentum. The RSI at 33.27 is Neutral, neither overbought nor oversold. The STOCH value of 28.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KOPRAN.

Kopran Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SAKAR	68 Neutral	₹7.26B	36.27		―	21.65%	73.84%
KILITCH	65 Neutral	₹7.87B	27.53		―	28.47%	78.96%
Sector *	64 Neutral	CHF26.61B	17.29	9.71%	2.35%	21.08%	2.84%
WANBURY	60 Neutral	₹8.24B	19.08		―	3.84%	-45.49%
KOPRAN	57 Neutral	₹7.72B	22.08		1.87%	-1.83%	-41.11%

Kopran Limited Corporate Events

Kopran Limited Announces Amalgamation with Kopran Laboratories

Kopran Limited has announced the submission of a Draft Scheme of Amalgamation, which involves the merger of Kopran Laboratories Limited into Kopran Limited. This strategic move is expected to streamline operations and enhance the company’s market position, subject to necessary approvals from regulatory authorities and stakeholders.